CHRISTIAN S. SCHADE has been a director since 2006.

Mr. Schade currently serves as the president and chief executive officer of Aprea Therapeutics, a privately held, clinical-stage biopharmaceutical company developing novel anticancer therapies targeting the tumor suppressor protein p53.

Prior to joining Aprea Therapeutics, Mr. Schade was the chief executive officer of Novira Therapeutics, Inc., an antiviral drug discovery company focused on first-in-class therapeutics for chronic HBV infection, until it was acquired by Johnson & Johnson. Before joining Novira Therapeutics, he served as executive vice president and chief financial officer of Omthera Pharmaceuticals, Inc., a specialty pharmaceuticals company focused on the clinical development of therapies for dyslipidemia. Previous to this role, Mr. Schade assumed a variety of senior leadership roles, including serving as executive vice president and chief financial officer at NRG Energy, senior vice president for administration and chief financial officer at Medarex Inc., and as managing director at Merrill Lynch, leading the European Corporate Funding Group. He also held various corporate finance and capital markets roles in New York and London for both Merrill Lynch and JP Morgan Chase & Co.

Currently, Mr. Schade serves on the Board of Directors of Indivior,plc, and Sapience Therapeutics.

Mr. Schade received an A.B. degree from Princeton University, and received an M.B.A. from the Wharton School at the University of Pennsylvania.